Evidence map›Paper›PMID 42681223›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Generation of Xenopus Transgenic Lines Using I-SceI.

Anita Abu-Daya, Anna Noble

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anita Abu-DayaEuropean Xenopus Resource Centre, University of Portsmouth, Portsmouth, UK.
Anna NobleEuropean Xenopus Resource Centre, University of Portsmouth, Portsmouth, UK. anna.noble@port.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transgenic Xenopus lines can be generated with high efficiency using the I-SceI meganuclease, an enzyme that recognizes an 18-base pair DNA sequence. To enable this, the desired transgene must be flanked by one or two I-SceI recognition sites either in the plasmid or a PCR product. Following a brief in vitro digestion with I-SceI, the entire reaction mixture is microinjected into fertilized eggs. Within the embryo, the enzyme facilitates genomic integration of the transgene through a mechanism that remains unknown. Embryonic development after injections generally proceeds normally and transgene integration occurs in up to 70% of embryos.

Indexed as

Animals, Genetically ModifiedDeoxyribonucleases, Type II Site-SpecificGene Transfer TechniquesXenopusXenopus laevisAnimalsMicroinjectionsPlasmidsSaccharomyces cerevisiae ProteinsTransgenesDeoxyribonucleases, Type II Site-SpecificSaccharomyces cerevisiae ProteinsSCEI protein, S cerevisiaeGateway cloningI-SceI meganucleaseTransgenesisXenopus transgenics

Identifiers

PMID42681223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.